Vision Science: Can Rhodopsin Cure Blindness?  by Van Gelder, Russell N. & Kaur, Kuldeep
Current Biology
Dispatchesbehavioral states in C. elegans. Cell 154,
1023–1035.
12. Fang-Yen, C., Avery, L., and Samuel, A.D.T.
(2009). Two size-selective mechanisms
specifically trap bacteria-sized food particles
in Caenorhabditis elegans. Proc. Natl. Acad.
Sci. USA 106, 20093–20096.
13. Bargmann, C.I., and Marder, E. (2013). From
the connectome to brain function. Nat.
Methods 10, 483–490.
14. Avery, L. (1993). Motor neuron M3 controls
pharyngeal muscle relaxation timing inCurCaenorhabditis elegans. J. Exp. Biol. 175,
283–297.
15. Raizen, D.M., and Avery, L. (1994). Electrical
activity and behavior in the pharynx of
Caenorhabditis elegans. Neuron 12, 483–495.
16. Dent, J.A., Davis, M.W., and Avery, L. (1997).
avr-15 encodes a chloride channel subunit
that mediates inhibitory glutamatergic
neurotransmission and ivermectin sensitivity
in Caenorhabditis elegans. EMBO J. 16,
5867–5879.
17. Chiang, J.-T.A., Steciuk, M., Shtonda, B.B.,
and Avery, L. (2006). Evolution of pharyngealrent Biology 25, R711–R731, August 17, 2015 ªbehaviors and neuronal functions in free-living
soil nematodes. J. Exp. Biol. 209, 1859–1873.18. Song, B.-M., and Avery, L. (2012). Serotonin
activates overall feeding by activating two
separate neural pathways in Caenorhabditis
elegans. J. Neurosci. 32, 1920–1931.19. Steciuk, M., Cheong, M.C., Waite, C., You,
Y.-J., and Avery, L. (2014). Regulation of
synaptic transmission at the Caenorhabditis
elegans M4 neuromuscular junction by an
antagonistic relationship between two
calcium channels. G3 4, 2535–2543.Vision Science: Can Rhodopsin Cure Blindness?Russell N. Van Gelder1,2,3,* and Kuldeep Kaur1
1Department of Ophthalmology, University of Washington School of Medicine, Seattle, WA 98104, USA
2Department of Biological Structure, University of Washington School of Medicine, Seattle, WA 98104, USA
3Department of Pathology, University of Washington School of Medicine, Seattle, WA 98104, USA
*Correspondence: russvg@uw.edu
http://dx.doi.org/10.1016/j.cub.2015.07.004
Outer retinal degeneration is the leading cause of blindness in the developed world. A new study now
demonstrates that ectopic expression of human rhodopsin in the inner retina, mediated by viral gene
therapy, can restore light sensitivity and some vision to mice blind from outer retinal degeneration.Blindness remains a major public health
challenge. Worldwide, 285 million people
are visually impaired, and about 39 million
legally blind [1]. In the developed world,
the leading causes of acquired and
hereditary blindess — age-related
macular degeneration and retinitis
pigmentosa, respectively — both share a
common pathophysiology. In each, the
rod and cone photoreceptors of the outer
retina undergo irreversible degeneration
(Figure 1A,B). While the inner retina
remains largely intact, in the absence
of outer retinal phototransduction no
visual information can be transmitted
from the retinal ganglion cells to the
brain. In this issue of Current Biology,
Cehajic-Kapetanovic and colleagues [2]
show that virally mediated gene therapy
of human rhodopsin, expressed in the
surviving cells of the inner retina, can
restore vision-like physiology and
behavior to mice blind from outer retinal
degeneration.
A number of approaches to restore
vision by conferring light sensitivity to the
remaining inner retinal cells have beenpursued in the past decade. Approaches
that have shown promise include use of
gene therapy with microbial opsins such
as Chlamydomonas channelopsin to
introduce light-regulated ion channels
to inner retinal cells [3–5]; gene therapy to
introduce the non-visual pigment
melanopsin to the inner retina [6];
one-component and two-component
optochemical photoswitches, which
utilize light-isomerizable channel agonists
to confer light sensitivity to remaining
inner retinal photoreceptors [7–9]; and
opto-electronic prostheses that stimulate
retinal ganglion cells directly [10]. The
latter approach is now approved in the
US for clinical use. While these methods
have all resulted in reconstituted
light-dependent firing of optic nerve fibers
and restored behavioral responses to
light, each has a number of potential
limitations. Use of channelopsins incurs
risks inherent in expressing foreign
proteins chronically in the retina, and
lack of signal amplification necessitates
relatively bright light for function.
Relative to native rod and cone opsins,melanopsin has slow kinetics and
relatively low sensitivity, which would
likely limit acuity. One-component
photoswitches lack cell-type specificity
while two-component photoswitches
require both gene therapy and a chemical
adjunct, which may limit practical
application. And opto-electronic
approaches are limited by the physics of
external stimulation of cells with resultant
low spatial resolution.
Ideally, a photopigment used to restore
visual functions via inner retinal
expression should be very light-sensitive,
have strong signal amplification, be native
to the organism, and be expressible in the
remaining cells of the degenerated retina.
Gene therapy with rhodopsin would seem
to fit these requirements. However, a
priori, rhodopsin would seem to be a poor
candidate, as its photocycle is intrinsically
tied to the G-protein transducin (which is
not expressed at high levels in the retina
outside the photoreceptors), and requires
continual chromophore replenishment
from the retinal pigment epithelium (RPE)
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Figure 1. Gene therapy rescue of vision in retinal degeneration.
(A) In the healthy retina, light penetrates from inner to outer retina to reach the cones and rods, which
transduce signals through horizontal, bipolar, amacrine, and ultimately retinal ganglion cells to the
brain. (B) In outer retinal degenerative diseases, loss of photoreceptors renders the retina insensitive to
light. (C) Gene therapy with AAV2/2 virus expressing human rhodopsin (hRod) under the control of the
CAG promoter results in expression of the photopigment in many surviving cells of the inner retina, and
results in restoration of light responses recognized by the brain. (D) More selective expression of
rhodopsin in a subset of bipolar cells is achieved by use of a virus in which expression is driven by the
grm6 promoter. This version appeared to restore the most natural visual function to blind mice.
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Dispatchesclosely tied to the physical interaction
between photoreceptors and RPE.
It is thus remarkable that Cehajic-
Kapetanovic et al. [2] succeeded with this
approach. The group used the rd1mutant
mouse as their model. These mice carry a
mutation in the phosphodiesterase 6b
gene which results in nearly complete
outer retinal degeneration by 3 months of
age (and is essentially similar to certain
forms of human retinitis pigmentosa [11]).
The researchers generated two
adenovirus-associated viral (AAV) gene
therapy vectors, each expressing human
rhodopsin cDNA under the control of aR714 Current Biology 25, R711–R731, Augusdifferent promoter. The first version, using
the CAG hybrid cytomegalovirus–chicken
actin promoter, expressed rhodopsin
ubiquitously throughout the remaining
inner retinal cells of rd1 mutant mice
(Figure 1C). In the second version, the
group expressed human rhodopsin under
control of the grm6 promoter, which
resulted in expression primarily in ON
bipolar interneurons (which normally sit
between the photoreceptors and retinal
ganglion cells comprising the optic nerve)
(Figure 1D).
To demonstrate restoration of
light-responsiveness, the authors firstt 17, 2015 ª2015 Elsevier Ltd All rights reservedused multi-electrode array recordings of
retinas from untreated and treated rd1
mice. Both viral constructs restored
robust light-dependent firing of numerous
retinal ganglion cells. The sensitivity
of these restored responses extended
to 1 x 1012 photons/cm2/s, which is
several orders of magnitude more
sensitive than that seen in initial
experiments with channelopsins. The
authors then performed recordings in
the lateral geniculate nucleus (the first
synaptic target of the optic nerve) and
showed that the gene therapy resulted in
significant changes in response with light
stimulus in the brain. The authors put the
treated mice through a gamut of visual
function tests, and showed significant
light-dependent behavior in treated
animals. Importantly, the group used both
temporal flicker and contrast gratings with
varying contrast ratios, and were thus
able to estimate the quality of restored
vision in temporal, contrast, and acuity
terms. The authors demonstrated
behavioral changes in mice treated with
the grm6 promoter to light up to 10 Hz
flicker frequency, 1:50 contrast ratio, and
acuity equivalent to 0.04 cycles per
degree (cpd). Wild-type mice have acuity
of 0.6 cpd under the same conditions. In
human terms, if ‘normal’ vision is 20/20
Snellen acuity, the gene therapy
approach would have restored 20/300
vision. Finally, the authors developed a
novel life-like movie of a swooping owl
and demonstrated that mice treated with
the grm6 promoter (but not the CAG
promoter) had significant, reproducible
LGN responses and behavioral avoidance
responses to the movie. Taken together,
these results strongly suggest that some
visual function was restored to these blind
animals by the gene therapy, particularly
for the animals treated with the grm6
vector.
While the restoration of some visual
function by this approach is a truly
remarkable achievement, a number of
questions still remain in considering
translation of this approach to the
treatment of human blindness. The
latencies exhibited by retinal ganglion
cells after brief light pulses were quite
broad, which might portend low temporal
resolution of vision ultimately. The authors
did not stress this system with very bright
light, which might be expected to bleach
rhodopsin (particularly in eyes with poor
Current Biology
Dispatchesretinal pigment epithelial function, which
is often the case clinically in patients with
photoreceptor degeneration). Of note, for
in vitro recordings, exogenous
retinaldehyde chromophore was required
to maintain sensitivity. While the ON-
bipolar pathway has been shown to be
necessary for normal human vision [12],
its sufficiency for creating visual
information is unclear. Normal vision
occurs over a remarkable range of
intensities and contrast levels, which is
made possible by multiple light
adaptation mechanisms [13]. It is unclear
which if any adaptation mechanisms
will be functional in the rescued retina.
Finally, restoration of function in a
rod-dominant retina like that of a
mouse may be quite different from
that in a cone-dominant human — if
color-specific ganglion cells are
stimulated uniformly by upstream
rhodopsin gene therapy, what color(s)
would one see in the world?
This work also raises some fascinating
physiology questions. While rhodopsin
has been known to be a promiscuous
G-protein coupled receptor [14,15], its
efficiency in signal transduction in the
bipolar and other inner retinal cells is
remarkable. What G-protein is mediating
these effects, and will there be
compensatory changes in its signaling
with chronic expression of the receptor?
How is the rhodopsin photocycle
mediated in these animals? Normally the
close apposition of rods and RPE is
thought to be important for the
chromophore photocycle [16]; is the
RPE responsible for the recycling of
chromophore in these degenerated
animals as well? If so, will utility of this
approach be limited in patients with RPE
dysfunction such as in atrophic macular
degeneration?
The current work is similar in concept to
the recent description of rescue of visual
function in the rd1mouse using a chimeric
melanopsin/mGluR6 metabotropic
glutamate receptor gene therapy
construct [17]. Similar to the current work,
this protein was driven by the
grm6 promoter in ON-bipolar cells
using an AAV viral vector. Interestingly,
similar to rhodopsin, this construct
also restored light responses to blind
retinas with a range of latencies,
although the sensitivity of responses
using the chimeric protein appeared toCurbe about one log less than for the
rhodopsin-AAV construct. However,
the measured visual acuity (using
optokinetic reflex testing) of melanopsin/
mGluR6-rescued rd1 mice was about
0.15 cycle/degree, higher than that
described in the current work for
rhodopsin (with the caveat that different
tests for visual acuity were employed in
the two studies).
The demonstration of rescue of visual
function by rhodopsin and chimeric
G-protein coupled receptor gene
therapies targeted at ON-bipolar cells are
milestones in efforts to reverse blindness.
The natural advantages of using native
proteins with intrinsic signal amplification
will immediately make this an attractive
approach for translation to clinical use.
As gene therapy in the retina appears to
be safe and efficacious (as demonstrated
by clinical trials with AAV-mediated
expression of RPE65 for Leber congenial
amaurosis [18,19]), the path to clinical
translation for rhodopsin and similar
therapies is clear.
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